Samsung Bioepis Begins First Phase 1 Clinical Trial for ADC New Drug
Samsung Bioepis has initiated Phase 1 clinical trials for its antibody-drug conjugate (ADC) new drug candidate, SBE303.
According to ClinicalTrials.gov, the clinical trial information disclosure site of the U.S. National Institutes of Health (NIH), the Phase 1 trial of SBE303 began last month and will continue until July 2030, targeting 149 patients with advanced solid tumors worldwide.
This clinical trial will evaluate the safety, tolerability, and efficacy of SBE303.
SBE303 is Samsung Bioepis's first new drug and targets Nectin-4, which is observed in tumor cells.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
This year, the Phase 1 clinical trial plan for this drug was also approved in Korea.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.